Clinical effects of date palm (Phoenix dactylifera L.): A systematic review on clinical trials.

Clinical effects Clinical trials Date Palm Phoenix dactylifera L. Systematic review

Journal

Complementary therapies in medicine
ISSN: 1873-6963
Titre abrégé: Complement Ther Med
Pays: Scotland
ID NLM: 9308777

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 14 01 2020
revised: 08 04 2020
accepted: 04 05 2020
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 3 11 2020
Statut: ppublish

Résumé

The aim of present study was to review and categorize the clinical trials investigating the clinical effects of different botanical parts of dates compared with any controls. All clinical trials (randomized, pilot, quasi-experimental, cross-over. and non-randomized clinical trials) evaluating the clinical effects of date palm from 2000 until August 2019 in English and Persian languages were included in this systematic review. The methodological quality of the included studies was evaluated according to the risk of bias assessment of Cochrane handbook of systematic reviews, and then reported using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Twenty-six studies met the inclusion criteria. Studies were performed in 8 categories based on different botanical parts of date palm. These categories were obstetrics, gynecology, oncology, dermatology, hematology, gastroenterology, endocrinology, metabolism, and infertility. A total of 38 % of included studies were randomized controlled trials. Further, 80 % of the included studies had performance and detection bias. Finally, about 50 % of them had selection bias and about 20 % had attrition and reporting bias. The widespread consumption of date palm as medicinal and botanical plant suggests the importance of this plant in human healthcare. The clinical trials conducted so far have explained a number of clinical effects of date palm. However, there is not enough clinical evidence to support the clinical effects in other review articles and traditional medical systems, and further randomized controlled trials with robust designs and methods are required.

Identifiants

pubmed: 32507440
pii: S0965-2299(20)30111-4
doi: 10.1016/j.ctim.2020.102429
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102429

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Alireza Bagherzadeh Karimi (A)

Department of Persian Medicine, School of Traditional Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: bagerzadeha@tbzmed.ac.ir.

Asghar Elmi (A)

Department of Orthopedic Surgeries, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: maralan-bagherzadeh@hotmail.com.

Arman Zargaran (A)

Department of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: arman_zargaran@yahoo.com.

Mojgan Mirghafourvand (M)

Department of Persian Medicine, School of Traditional Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Midwifery Department, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: mirghafourvand@gmail.com.

Seyed Mohammad Bagher Fazljou (SMB)

Department of Persian Medicine, School of Traditional Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: dr.fazljou@yahoo.com.

Mostafa Araj-Khodaei (M)

Department of Persian Medicine, School of Traditional Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Mostafaa33@gmail.com.

Roghayeh Baghervand Navid (R)

Department of Persian Medicine, School of Traditional Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: rbaghervand@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH